Company Profile
Heron Therapeutics Stock Price, News & Analysis
- Ticker:
- HRTX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.50 USD (-1.15%)
Close
Last updated: August 6, 2026
85.2M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, HRTX closed down 1.15% at $0.4990. No new same-company headline was identified in the current news window.
Company overview
Acute-Care Medicines
Heron Therapeutics commercializes medicines used in surgical pain management and oncology supportive care. Its portfolio is designed for administration in hospitals, ambulatory surgery centers and infusion settings.
ZYNRELEF
ZYNRELEF is an extended-release local anesthetic combining bupivacaine and meloxicam for postoperative pain. Heron is developing a ready-to-use prefilled syringe intended to improve preparation and operating-room efficiency.
Oncology Supportive Care
CINVANTI and APONVIE are injectable antiemetic products used to prevent nausea and vomiting associated with chemotherapy or surgery. These products complement the company's acute-care commercial infrastructure.
Future catalysts
Twelve-month stability data for the ZYNRELEF prefilled-syringe registration batches in the first half of 2027.
Recent news
- 01
Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026
Source: Heron Therapeutics
- 02
U.S. District Court Issues Decision Regarding CINVANTI® Patents
Source: Heron Therapeutics
- 03
Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance
Source: Heron Therapeutics
- 04
Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026
Source: Heron Therapeutics
- 05
Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results
Source: Heron Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Heron Therapeutics (HRTX)?
Heron Therapeutics (HRTX) most recently closed at 0.50 USD, a -1.15% move versus the previous session.
What is the market cap of Heron Therapeutics (HRTX)?
Heron Therapeutics currently has a market capitalization of 85.2M USD on BioPharmSignal.
What does Heron Therapeutics do?
Acute-Care Medicines Heron Therapeutics commercializes medicines used in surgical pain management and oncology supportive care. Its portfolio is designed for administration in hospitals, ambulatory surgery centers and infusion settings. ZYNRELEF ZYNRELEF is an extended-release local anesthetic combining bupivacaine and meloxicam for postoperative pain....
On which exchange is HRTX stock listed?
Heron Therapeutics (HRTX) is associated with NASDAQ, United States, Biopharma.
What is Acute-Care?
Acute-Care Medicines Heron Therapeutics commercializes medicines used in surgical pain management and oncology supportive care.
Which conditions is Heron Therapeutics targeting with Acute-Care?
Heron Therapeutics is associated with oncology based on its company overview and current catalyst commentary.
How does Heron Therapeutics describe recent progress with Acute-Care?
Twelve-month stability data for the ZYNRELEF prefilled-syringe registration batches in the first half of 2027.
What is Medicines?
Acute-Care Medicines Heron Therapeutics commercializes medicines used in surgical pain management and oncology supportive care.